1 Title: Impact of long-COVID on health-related quality of life in Japanese COVID-19

2 patients

3 Running title: HRQOL of long-COVID

4

5 Shinya Tsuzuki, MD, MSc^{1,2*}; Yusuke Miyazato, MD³; Mari Terada, MPH^{3,4}, Shinichiro

6 Morioka, MD³; Norio Ohmagari, MD, PhD^{1,3}; Philippe Beutels, PhD²

7 ¹ AMR Clinical Reference Center, National Center for Global Health and Medicine,

8 Tokyo, Japan

9 ² Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

10 ³ Disease Control and Prevention Center, National Center for Global Health and

11 Medicine, Tokyo, Japan

12 ⁴ Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo,

13 Japan

14

15

16 *Corresponding author: Shinya Tsuzuki, MD, MSc

17 National Center for Global Health and Medicine

18 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

19 University of Antwerp

20 Prinsstraat 13, 2000 Antwerpen, Belgium

21 Tel: +81(0)3-3202-7181

22 Email: stsuzuki@hosp.ncgm.go.jp

23

24 **Abstract**

25 **Background:** The empirical basis for a quantitative assessment of the disease burden
26 imposed by long-COVID is currently scant. We aimed to assess the disease burden
27 caused by long-COVID in Japan.

28 **Methods:** We conducted a cross sectional self-report questionnaire survey. The
29 questionnaire was mailed to 530 eligible patients, who were recovered from acute
30 COVID-19 in April 2021. Answers were classified into two groups; participants who
31 have no symptom and those who have any ongoing symptoms that lasted longer than
32 four weeks at the time of the survey. We compared health-related quality of life scores
33 estimated by the EQ-5D-3L questionnaire between these two groups after adjusting
34 basic characteristics of the participants by propensity score matching.

35 **Results:** 349 participants reported no symptoms and 108 reported any symptoms at the
36 time of the survey. The participants who reported any symptoms showed a lower value
37 on a Visual Analogue Scale (median 70 [IQR 60-80]) and on the EQ-5D-3L (median
38 0.81 [IQR 0.77-1.0]) than those reporting no symptoms (median 85 [IQR 75-90] and 1.0
39 [IQR 1.0-1.0], respectively). After adjusting for background characteristics, these trends
40 did not change substantially (Visual Analog Scale: median 70 [IQR 60-80] vs 80 [IQR
41 77-90], EQ-5D-3L: median 0.81 [IQR 0.76-1.0] vs 1.0 [IQR 1.0-1.0]).

42 **Conclusions:** Due to their long duration, long-COVID symptoms represent a substantial

43 disease burden expressed in impact on health-related quality of life.

44 **Trial registration:** Not applicable.

45

46 **Keywords:** COVID-19; disease burden; Quality of life; long-COVID

47

48 **Word count:** 3,000

49

50

51

52 **Background**

53 Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus, has become a
54 global health threat [1]. Not only its acute phase of disease, but so-called “long-COVID”
55 is also a cause of substantial disease burden [2,3]. A systematic review reported that
56 80% of patients developed one or more long-term symptoms and the prevalence of 55
57 long-term effects of COVID-19 [4].

58 There is no clear definition of long-COVID so far, however, the National Institute
59 for Health and Care Excellence (NICE) in The UK defined it as “signs and symptoms
60 that develop during or following an infection consistent with covid-19 and which
61 continue for more than four weeks and are not explained by an alternative diagnosis” [5].
62 This term includes ongoing symptomatic COVID-19, from four to 12 weeks
63 post-infection, and post-COVID-19 syndrome, beyond 12 weeks post-infection [6].

64 The symptoms of long-COVID are various and often different from the acute phase
65 of COVID-19. Miyazato and colleagues reported that the mean time from COVID-19
66 symptom onset to the emergence of alopecia was 58.6 days and one of patients
67 presented dysosmia after 92 days after symptom onset [7]. Other symptoms such as
68 general fatigue [8,9], respiratory symptoms [10,11], cognitive and mental health
69 disorder [12,13], and so forth [14,15] have been reported as long-COVID.

70 Considering its chronic phase, the disease burden of COVID-19 should be larger

71 than that of other respiratory infections due to length and variety of the symptoms.
72 However, the empirical basis for a quantitative assessment of the disease burden
73 imposed by long-COVID is currently scant. An important element towards disease
74 burden assessment is health-related quality of life impact. The objective of the present
75 study is to collect and analyse empirical information on the health-related quality of life
76 (HRQoL) due to long-COVID.

77

78

79

80 **Methods**

81 **Settings**

82 We conducted a survey in which a self-report questionnaire was mailed to eligible
83 patients who had recovered from COVID-19 in April 2021 with two reminders 2 weeks
84 and 1 month later. Potential participants were recruited from patients who had recovered
85 from COVID-19 and visited the outpatient service of the Disease Control and
86 Prevention Center (DCC) in the NCGM in order to obtain pre-donation screening test
87 for COVID-19 convalescent plasmapheresis (Another study named “Collection and
88 antibody measurement of Convalescent plasma foreseeing the use for COVID-19
89 treatment”). 530 patients who had recovered from COVID-19 (70 out of 448 needs
90 supplementary oxygen support) and visited the outpatient service of the Disease Control
91 and Prevention Center (DCC) in National Center for Global Health and Medicine
92 (NCGM), Tokyo, Japan from 1st February 2020 to 31st March 2021. Participation in the
93 survey was voluntary and not anonymous. Participants were requested to complete and
94 return the questionnaire. 457 of 530 (86.2%) patients completely answered the
95 questionnaire and were included in the analysis.

96

97 **Statistical analysis**

Answers were classified into two groups; participants who have no symptom and those who have any ongoing symptoms that lasted longer than four weeks at the time of the survey. We compared visual analogue scale (VAS) and HRQoL values estimated by the EQ-5D-3L questionnaire [16] by Japanese value set [17] between two groups using Mann-Whitney U test, after adjusting basic characteristics of the participants by one-to-one propensity score matching (nearest neighbour pair matching, caliper = 0.2) calculated by multivariate logistic regression model predicting the likelihood of having ongoing symptoms [18,19]. We included age, sex, BMI, smoking, drinking, hypertension, diabetes, chronic obstructive lung diseases, malignancy, use of antivirals, use of systemic steroids, and severe COVID-19 disease during admission (use of mechanical ventilation or extracorporeal membrane oxygenation during admission, according to the definition by a report of national registry data in Japan [20]). The standardized mean difference was used to measure covariate balance, and an absolute standardized difference above 20% was interpreted as a meaningful imbalance. Two-sided p values of <0.05 were considered to show statistical significance. All analyses were conducted by R, version 4.0.5 [21].

Ethics approval

116 According to local ethical guidelines, responses to questionnaire were regarded as
117 patient consent. This study was reviewed and approved by the Ethics Committee of the
118 Center Hospital of the NCGM (NCGM-G-004121-00).

119

120

121

122 **Results**

123 Table 1 shows the basic characteristics of the participants. 457 patients recovered from
124 acute phase of COVID-19 and 108 of them presented at least one symptom. The
125 proportion of female was larger in “Any symptom” group than that in “No symptom”
126 group. There was no substantial difference between the two groups in terms of their age
127 and medical history. Crude comparison of VAS and QOL showed that “Any symptom”
128 group had lower VAS and QOL values than the “No symptom” group did (VAS: 70 vs
129 85, QOL: 0.81 vs 1.0, respectively).

130

131 (Table 1)

132

133 Table 2 describes the characteristics of the data after propensity score matching.
134 91 pairs included in the matched data and 17 of “Any symptom” group were discarded.
135 Adjusted comparison of VAS and QOL showed a similar trend to the results of crude
136 comparison. Both VAS and QOL were lower in the “Any symptom” group (VAS: 70 vs
137 80, QOL: 0.81 vs 1.0, respectively).

138

139 (Table 2)

140

141 Table 3 describes the characteristics of “long-COVID” symptoms. We defined
142 “long-COVID” as the status in which any symptoms attributed to SARS-nCoV-2
143 infection lasting more than four weeks in the present study. 201 of 457 (44.0%)
144 participants reported at least one symptom after four weeks have passed since their
145 symptom onset due to COVID-19. The most common symptom of long-COVID was
146 general fatigue. 58 of 457 (12.7%) participants have had general fatigue longer than
147 four weeks. The second most common symptom was alopecia. 55 of 457 (12.0%)
148 participants have experienced hair loss worse than usual.

149

150 (Table 3)

151

152 Figure 1 and 2 show a violin plot of VAS and QOL value, respectively. The
153 “Any symptom” group showed greater variance in both indicators.

154

155 (Figure 1)

156

157 (Figure 2)

158

159

160 **Discussion**

161 The present study demonstrated that the phenomenon we called “long-COVID” can
162 impair the HRQOL substantially. This would be another important aspect of COVID-19
163 to consider because it implies a heavier disease burden to us than other influenza like
164 illnesses (ILIs) do, not only due to its severity but also the characteristics of its chronic
165 phase. In the first place, COVID-19 showed higher case-fatality than other ILIs [22–24].
166 Additionally, it might cause a substantial burden through accumulated mild disease
167 only.

168 Furthermore, the frequency and the duration of symptoms due to “long-COVID”
169 are also noteworthy. Our results showed that nearly half of the patients who recovered
170 from acute COVID-19 (201/457) experienced any symptoms lasting more than four
171 weeks. As for patients who required supplementary oxygen support, 32 out of 70
172 (45.7%) presented any symptoms longer than four weeks. The precise duration of such
173 symptoms was not obvious because more than 100 participants reported that their
174 symptoms were still ongoing, nevertheless, we can say that the symptoms attributed to
175 “long-COVID” often continue several months. Albeit the HRQOL value of the

176 participants who have any “long-COVID” symptoms was higher than that of the acute
177 phase of other ILIs reported by a previous study in Japan (0.81 vs 0.66, respectively)
178 [25], QOL lost attributed to “long-COVID” should be greater than that due to the acute
179 phase of other ILIs because of its duration.

180 These results suggest that prevention is more important in COVID-19
181 countermeasures than other ILIs because effective treatment of “long-COVID” is not
182 clearly established yet [6,26]. Although there is no doubt that vaccination against
183 SARS-CoV-2 will reduce the risk of fatal and severe COVID-19 [27–29], its
184 effectiveness against “long-COVID” is not demonstrated yet. This may provide an
185 additional incentive to prevent SARS-CoV-2 infection even in the absence of known
186 risk factors of severe illness.

187 There are several limitations in our study. First, our results are based on the
188 questionnaire survey then there are some recall biases in participants’ responses.
189 Similarly, the potential participants were enrolled from the visitors of outpatient
190 department at the national center hospital of infectious diseases in Japan, then the study
191 population might be influenced by selection biases. In addition, we could not take “new
192 variants” into consideration. The difference in severity, infectiousness, and so forth
193 between such new variants and old ones were already reported [30–32], however, there

194 is no solid evidence about the frequency and the severity of “long-COVID” symptoms
195 in new variants. This should be the subject of future study.

196 In addition, we should be careful about the representativeness of the data when
197 we interpret the results because our survey includes a comparatively small number of
198 participants from Japan. However, the response rate of our survey was extremely high
199 (86.2%), and non-response bias may therefore be limited. Furthermore, we compared
200 VAS and EQ-5D-3L values after adjusting participants’ background by propensity score
201 matching.

202

203 **Conclusions**

204 What we call “long-COVID” brings us substantial disease burden in addition to
205 the burden attributed to the acute phase of COVID-19. This additional burden makes the
206 whole disease burden of COVID-19 heavier, making prevention strategies all the more
207 important. The influence of vaccination and variants on “long-COVID” should be
208 examined in the near future.

209

210

211 **Declarations**

212 **Ethics approval**

213 This study was reviewed and approved by the Ethics Committee of the Center Hospital
214 of the NCGM (NCGM-G-004121-00)

215

216 **Consent for publication**

217 According to local ethical guidelines, responses to questionnaire were regarded as
218 patient consent.

219

220 **Availability of data and materials**

221 The data that support the findings of this study are available upon request from the
222 corresponding author. The data are not publicly available due to privacy or ethical
223 restrictions.

224

225 **Competing interests**

226 PB reports grants from the EU's SC1-PHE-CORONAVIRUS-2020 programme, Pfizer,
227 GlaxoSmithKlein, and European Commission IMI, unrelated to this work.

228

229 **Funding**

230 This research was funded by JSPS KAKENHI [Grant number 18K17369], a grant for
231 the National Center for Global Health and Medicine [20A05], AMED under Grant
232 Number JP20fk0108502 and the Health and Labour Sciences Research Grant,
233 “Research for risk assessment and implementation of crisis management functions for
234 emerging and re-emerging infectious diseases.”

235

236 **Authors’ contributions**

237 Shinya Tsuzuki: Conceptualization, Funding Acquisition, Data Curation, Formal
238 Analysis, Methodology, Visualization, Original Draft Preparation. Yusuke Miyazato:
239 Data Curation, Review and Editing. Mari Terada: Data Curation, Review and Editing.
240 Shinichiro Morioka: Data Curation, Project Administration, Review and Editing. Norio
241 Ohmagari: Conceptualization, Funding Acquisition, Project Administration, Review and
242 Editing. Philippe Beutels: Supervision, Project Administration, Review & Editing.

243

244 **Acknowledgments**

245 We thank all the people who participated in our survey and study, “Collection and
246 antibody measurement of Convalescent plasma foreseeing the use for COVID-19

247 treatment”.

248

249

250

251

References

- 252 1. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of
253 Coronavirus Disease 2019 in China. *N Engl J Med*. 2020;382:1708–20.
- 254 2. del Rio C, Collins LF, Malani P. Long-term Health Consequences of COVID-19.
255 *JAMA* [Internet]. 2020 [cited 2020 Oct 6]; Available from:
256 <https://jamanetwork.com/journals/jama/fullarticle/2771581>
- 257 3. UK guidelines for managing long-term effects of COVID-19 - The Lancet [Internet].
258 [cited 2021 May 17]. Available from:
259 [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(21\)00847-3/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00847-3/fulltext)
- 260 4. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA,
261 Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and
262 meta-analysis. *Sci Rep*. 2021;11:16144.
- 263 5. Sivan M, Taylor S. NICE guideline on long covid. *BMJ*. British Medical Journal
264 Publishing Group; 2020;371:m4938.
- 265 6. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors,
266 and management. *BMJ*. 2021;374:n1648.
- 267 7. Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y, Tanaka K, et al. Prolonged
268 and Late-Onset Symptoms of Coronavirus Disease 2019. *Open Forum Infect Dis*.
269 2020;7:ofaa507.
- 270 8. Mandal S, Barnett J, Brill SE, Brown JS, Denny EK, Hare SS, et al.
271 ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging
272 abnormalities following hospitalisation for COVID-19. *Thorax*. 2021;76:396–8.
- 273 9. Carfi A, Bernabei R, Landi F, Gemelli Against COVID-19 Post-Acute Care Study
274 Group. Persistent Symptoms in Patients After Acute COVID-19. *JAMA*.
275 2020;324:603–5.
- 276 10. Goertz YMJ, Herck MV, Delbressine JM, Vaes AW, Meys R, Machado FVC, et al.
277 Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19

278 syndrome? ERJ Open Research [Internet]. European Respiratory Society; 2020 [cited
279 2021 Jul 31]; Available from:
280 <https://openres.ersjournals.com/content/early/2020/09/01/23120541.00542-2020>

281 11. Tenforde MW. Symptom Duration and Risk Factors for Delayed Return to Usual
282 Health Among Outpatients with COVID-19 in a Multistate Health Care Systems
283 Network — United States, March–June 2020. MMWR Morb Mortal Wkly Rep
284 [Internet]. 2020 [cited 2021 Jul 31];69. Available from:
285 <https://www.cdc.gov/mmwr/volumes/69/wr/mm6930e1.htm>

286 12. Mazza MG, De Lorenzo R, Conte C, Poletti S, Vai B, Bollettini I, et al. Anxiety and
287 depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain,
288 Behavior, and Immunity. 2020;89:594–600.

289 13. Halpin SJ, McIvor C, Whyatt G, Adams A, Harvey O, McLean L, et al.
290 Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection:
291 A cross-sectional evaluation. J Med Virol. 2021;93:1013–22.

292 14. Boscolo-Rizzo P, Borsetto D, Fabbris C, Spinato G, Frezza D, Menegaldo A, et al.
293 Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic
294 COVID-19. JAMA Otolaryngol Head Neck Surg. 2020;146:729.

295 15. Puntmann VO, Carerj ML, Wieters I, Fahim M, Arendt C, Hoffmann J, et al.
296 Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently
297 Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1265.

298 16. Rabin R, Gudex C, Selai C, Herdman M. From translation to version management: a
299 history and review of methods for the cultural adaptation of the EuroQol
300 five-dimensional questionnaire. Value Health. 2014;17:70–6.

301 17. Tsuchiya A, Ikeda S, Ikegami N, Nishimura S, Sakai I, Fukuda T, et al. Estimating
302 an EQ-5D population value set: the case of Japan. Health Economics. 2002;11:341–53.

303 18. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational
304 studies for causal effects. :15.

305 19. Dolan P. Modeling valuations for EuroQol health states. Med Care.
306 1997;35:1095–108.

307 20. Matsunaga N, Hayakawa K, Terada M, Ohtsu H, Asai Y, Tsuzuki S, et al. Clinical
308 epidemiology of hospitalized patients with COVID-19 in Japan: Report of the
309 COVID-19 REGISTRY JAPAN. Clin Infect Dis. 2020;

310 21. R Core Team. R: A Language and Environment for Statistical Computing. Vienna,
311 Austria: R Foundation for Statistical Computing; 2018.

312 22. Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, Pérez-Olmeda M, Yotti R,
313 Oteo-Iglesias J, et al. Infection fatality risk for SARS-CoV-2 in community dwelling
314 population of Spain: nationwide seroepidemiological study. BMJ. 2020;371:m4509.

315 23. Poletti P, Tirani M, Cereda D, Trentini F, Guzzetta G, Marziano V, et al.
316 Age-specific SARS-CoV-2 infection fatality ratio and associated risk factors, Italy,
317 February to April 2020. Eurosurveillance. European Centre for Disease Prevention and
318 Control; 2020;25:2001383.

319 24. van Asten L, Harmsen CN, Stoeldraijer L, Klinkenberg D, Teirlinck AC, de Lange
320 MMA, et al. Excess Deaths during Influenza and Coronavirus Disease and
321 Infection-Fatality Rate for Severe Acute Respiratory Syndrome Coronavirus 2, the
322 Netherlands. Emerg Infect Dis. 2021;27:411–20.

323 25. Tsuzuki S, Yoshihara K. The characteristics of influenza-like illness management in
324 Japan. BMC Public Health. 2020;20:568.

325 26. Carson G, Carson G, Sigfrid L, Olliaro P, Norton A, Paparella G, et al. Research
326 priorities for Long Covid: refined through an international multi-stakeholder forum.
327 BMC Medicine. 2021;19:84.

328 27. Escobar LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe
329 coronavirus disease 2019 (COVID-19). PNAS. National Academy of Sciences;
330 2020;117:17720–6.

331 28. Pilishvili T. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and
332 Moderna COVID-19 Vaccines Among Health Care Personnel — 33 U.S. Sites,
333 January–March 2021. MMWR Morb Mortal Wkly Rep [Internet]. 2021 [cited 2021 Jun
334 21];70. Available from: <https://www.cdc.gov/mmwr/volumes/70/wr/mm7020e2.htm>

335 29. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety
336 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. New England Journal of

- 337 Medicine [Internet]. Massachusetts Medical Society; 2020 [cited 2021 Feb 6]; Available
338 from: <https://www.nejm.org/doi/10.1056/NEJMoa2034577>
- 339 30. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L.
340 Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1:
341 matched cohort study. BMJ. 2021;n579.
- 342 31. Grint DJ, Wing K, Williamson E, McDonald HI, Bhaskaran K, Evans D, et al. Case
343 fatality risk of the SARS-CoV-2 variant of concern B.1.1.7 in England, 16 November to
344 5 February. Euro Surveill. 2021;26.
- 345 32. Patone M, Thomas K, Hatch R, Tan PS, Coupland C, Liao W, et al. Analysis of
346 severe outcomes associated with the SARS-CoV-2 Variant of Concern 202012/01 in
347 England using ICNARC Case Mix Programme and QResearch databases. medRxiv.
348 Cold Spring Harbor Laboratory Press; 2021;2021.03.11.21253364.

349

350

351 **Table 1. Characteristics of participants**

	No symptom	Any symptom	<i>P</i> value*	SMD
Number	349	108		
Age	48 [39-55]	47 [40-54]	0.724	0.001
Male	188 (53.9)	38 (35.2)	0.001	< 0.383
BMI	23.2 [21.1-25.6]	23.4 [20.9-26.9]	0.453	0.163
Smoking	130 (37.2)	38 (35.5)	0.819	0.036
Drinking	290 (83.1)	86 (79.6)	0.471	0.089
Hypertension	52 (14.9)	14 (13.0)	0.754	0.056
Diabetes	23 (6.6)	5 (4.6)	0.646	0.085
COPD	3 (0.9)	0 (0.0)	1.0	< 0.132
Malignancy	6 (1.7)	0 (0.0)	0.343	0.187
Use of antivirals	62 (18.8)	22 (20.8)	0.672	0.049
Use of steroids	40 (12.8)	13 (13.3)	0.865	0.013
Severe disease[†]	7 (2.1)	6 (5.6)	0.092	0.183
Oxygen support	44 (12.6)	13 (13.3)	0.870	0.027
VAS	85 [75-90]	70 [60-80]	< 0.001	0.810
QOL	1.0 [1.0-1.0]	0.81 [0.77-1.0]	< 0.001	0.845

352 Median [interquartile range] for continuous variables, number (%) for categorical

353 variables.

354 *Mann-Whitney U test for continuous variables, Fisher's exact test for categorical

355 variables.

356 [†] Use of mechanical ventilation or extracorporeal membrane oxygenation during

357 admission.

358 SMD: standardized mean difference, BMI: Body Mass Index, COPD: chronic

359 obstructive pulmonary disease, VAS: Visual Analogue Scale, QOL: Quality of Life

360

361 **Table 2. Characteristics of participants after propensity score matching**

	No symptom	Any symptom	<i>P</i> value*	SMD
Number	91	91		
Age	46 [39-52]	46 [39-54]	0.515	0.123
Male	29 (31.9)	29 (31.9)	1.0	< 0.001
BMI	22.7 [20.8-26.8]	23.4 [20.9-26.5]	0.801	0.051
Smoking	30 (33.0)	30 (33.0)	1.0	< 0.001
Drinking	68 (74.7)	74 (81.3)	0.371	0.160
Hypertension	7 (7.7)	10 (11.0)	0.612	0.113
Diabetes	5 (5.5)	5 (5.5)	1.0	< 0.001
COPD	0 (0.0)	0 (0.0)	NA	< 0.001
Malignancy	0 (0.0)	0 (0.0)	NA	< 0.001
Use of antivirals	16 (17.6)	16 (17.6)	1.0	0.063
Use of steroids	14 (15.4)	12 (13.2)	0.833	< 0.001
Severe disease[†]	3 (3.3)	3 (3.3)	1.0	< 0.001
VAS	80 [77-90]	70 [60-80]	< 0.001	0.763
QOL	1.0 [1.0-1.0]	0.81 [0.76-1.0]	< 0.001	0.80

362 Median [interquartile range] for continuous variables, number (%) for categorical

363 variables.

364 *Mann-Whitney U test for continuous variables, Fisher's exact test for categorical

365 variables.

366 [†] Use of mechanical ventilation or extracorporeal membrane oxygenation during

367 admission.

368 SMD: standardized mean difference, BMI: Body Mass Index, COPD: chronic

369 obstructive pulmonary disease, VAS: Visual Analogue Scale, QOL: Quality of Life

370

371 **Table 3. Details of symptoms lasted longer than four weeks in the participants**

	Number	Duration (days)
Number of symptoms	457	
At least 1	201 (44.0)	
1	73 (16.0)	
2	46 (10.1)	
3	47 (10.3)	
4 and more	34 (7.4)	
Fatigue	58 (12.7)	50 [30-60]
Hair loss	55 (12.0)	60 [30-90]
Cough	54 (11.8)	40 [30-60]
Dysosmia	47 (10.3)	45 [30-60]
Dysgeusia	47 (10.3)	35 [30-60]
Shortness of breath	36 (7.9)	42.5 [30-60]
Loss of concentration	34 (7.4)	40 [30-90]
Depression	29 (6.3)	40 [30-60]

372 Absolute number (%) for the number of participants, median [interquartile range] for

373 the duration of symptoms.

374

375 **Figure 1. Violin plot of visual analogue scale**

376 Red colour represents “No symptom” group and blue colour represents “With symptom”

377 group.

378

379 **Figure 2. Violin plot of Quality of Life**

380 Red colour represents “No symptom” group and blue colour represents “With symptom”

381 group.